InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

- Current share price for RCE : $0.360

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$110 Recce Completes Capital Raising of $27.95m 23 Sep 2020 9:57AM $1.635 $0.360 fallen by 77.98%
$110 Trading Halt 21 Sep 2020 9:26AM $1.635 $0.360 fallen by 77.98%
$110 R327 Phase I Study - Australia's CMAX Clinical Facility 10 Sep 2020 11:57AM $1.660 $0.360 fallen by 78.31%
$110 Comment on Media Article Published in AFR 8 Sep 2020 6:19PM $1.625 $0.360 fallen by 77.85%
$110 Positive & Concentration-Dependent Efficacy Against COVID-19 8 Sep 2020 1:59PM $1.475 $0.360 fallen by 75.59%
$110 Trading Halt 7 Sep 2020 12:00PM $1.475 $0.360 fallen by 75.59%
$110 Pause in Trading 7 Sep 2020 9:59AM $1.475 $0.360 fallen by 75.59%
$110 Change of Director's Interest Notice 2 Sep 2020 5:27PM $1.560 $0.360 fallen by 76.92%
$110 Change of Director's Interest Notice 2 Sep 2020 5:27PM $1.560 $0.360 fallen by 76.92%
$110 Recce Pharmaceuticals Receives Innovation Connections Grant 1 Sep 2020 9:05AM $1.470 $0.360 fallen by 75.51%
$110 Cleansing Statement 28 Aug 2020 6:37PM $1.360 $0.360 fallen by 73.53%
$110 Appendix 2A 28 Aug 2020 6:26PM $1.360 $0.360 fallen by 73.53%
$110 Appendix 4G 28 Aug 2020 5:57PM $1.360 $0.360 fallen by 73.53%
$110 2020 Annual Report 28 Aug 2020 5:49PM $1.360 $0.360 fallen by 73.53%
$110 Appendix 4E 28 Aug 2020 5:43PM $1.360 $0.360 fallen by 73.53%
$110 Recce Pharmaceuticals Appoints James Graham as CEO 28 Aug 2020 5:40PM $1.360 $0.360 fallen by 73.53%
$110 Appointment of H. Pylori Expert Prof Sutton to Dev Program 21 Aug 2020 2:25PM $1.350 $0.360 fallen by 73.33%
$110 Conversion of Performance Shares 17 Aug 2020 9:57AM $1.280 $0.360 fallen by 71.88%
$110 Investor Presentation 4 Aug 2020 1:04PM $1.285 $0.360 fallen by 71.98%
$110 Positive Oral Data on New RECCE 435 Against H. pylori 4 Aug 2020 10:36AM $1.150 $0.360 fallen by 68.70%
$110 Appendix 4C and Activity Report 31 Jul 2020 11:42AM $1.290 $0.360 fallen by 72.09%
$110 Opening Address at 2020 World Antibiotic Resistance Congress 23 Jul 2020 2:33PM $1.305 $0.360 fallen by 72.41%
$110 Correction - CSIRO SARS-CoV-2 Antiviral Screening Program 20 Jul 2020 9:55AM $1.390 $0.360 fallen by 74.10%
$110 US Researchers to Test RECCE in Expanded SARS-CoV-2 Program 16 Jul 2020 10:07AM $1.145 $0.360 fallen by 68.56%
$110 Pause in Trading 16 Jul 2020 10:01AM $1.145 $0.360 fallen by 68.56%

426 - 450 of 729 results

Page 18 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.